DGAP-Media / 2019-11-15 / 09:00
*Hennigsdorf, Germany, November 15, 2019 -* SphingoTec GmbH ("sphingotec")
today announced that latest advancements in the development of its portfolio
of novel biomarkers and diagnostic solutions will be showcased at Medica
2019 in Düsseldorf, Germany. To improve the management of critically ill
patients in acute care settings through timely diagnostic, sphingotec has
started making available novel biomarkers that complement a broad menu of
existing standard of care tests on its Nexus IB10 point-of-care platform.
Sepsis, septic shock, and acute failure of vital organs such as heart and
kidney, are diagnostically underserved medical conditions in critical care
settings. Based on a deep understanding of the disease biology, sphingotec
has developed novel biomarkers to tackle these unmet needs through
diagnostic solutions that allow early identification and monitoring of
critically ill patients. sphingotec's near-term pipeline of novel assays on
the Nexus IB10 platform includes:
· IB10 sphingotest(R) DPP3 launched in August 2019 is the first CE-IVD
point-of-care biomarker test able to quantify DPP3 blood-plasma levels, a
novel and unique biomarker for assessing cardio-renal pathway disruptions
leading to short-term organ dysfunction [1, 2]. DPP3 is at the core of a
novel disease mechanism that has a causal role in cardiac and renal
dysfunction.
· IB10 sphingotest(R) penKid(R), to be launched in early 2020 as a CE-IVD
test, is the first point-of-care assay for Proenkephalin, a unique and
proprietary biomarker for real-time assessment of kidney function.
Previous studies on more than 30,000 critically ill patients admitted to
emergency departments (EDs) or intensive care units (ICUs) with congestive
heart failure [3] or sepsis [4] demonstrated that Proenkephalin levels
change dynamically with the actual kidney function independently from
comorbidities or inflammation [5]. The biomarker allows monitoring of
renal function in real-time and facilitates earlier detection and more
precise monitoring of acute kidney injury than the current
standard-of-care.
· IB10 sphingotest(R) bio-ADM(R) to be launched in mid-2020, is a first
point-of-care assay for bioactive Adrenomedullin, a unique biomarker for
real-time assessment of endothelial function [6]. Data from more than
20,000 patients confirm that measuring bio-ADM(R) levels adds value to
clinical decision making in ICUs and EDs. Increased blood levels of
bioactive Adrenomedullin have been demonstrated to precede endothelial
dysfunction, vascular leakage subsequent systemic vasodilation and shock
in sepsis [7]. Furthermore, it has been shown that elevated levels of
bioactive Adrenomedullin indicate the loss of endothelial function leading
to congestion in heart failure [8]. IB10 sphingotest(R) bio-ADM(R) not
only supports earlier clinical interventions but also the monitoring of
treatment success.
The Nexus IB10 point-of-care technology provides test results on whole blood
sample in only 20 minutes and can be flexibly deployed in emergency
departments, intensive care units, and any laboratory setting. In addition
to the increasing menu of assays for proprietary biomarkers, the platform
features a broad menu of 8 rapid tests for acute care settings including
parameters such as the Troponin-I, NT-proBNP, and D-Dimer. Following the
acquisition of Nexus Dx Inc., San Diego, USA, in 2018 from the Korean
manufacturer Samsung, sphingotec markets the Nexus IB10 point-of-care
platform through its continuously expanding distribution network. ###
*Visit sphingotec at Medica 2019*
sphingotec showcases its Nexus IB10 instrument and test portfolio as well as
its proprietary biomarkers for acute care conditions at Medica 2019 and
welcomes healthcare professionals as well as distributors and diagnostics
and pharmaceutical industry representatives interested in partnering at its
booth G52 in hall 3.
*References*
[1] Takagi et. al. (2019) Circulating dipeptidyl-peptidase 3 and alteration
in hemodynamics in cardiogenic shock: Results from the OptimaCC Trial,
European Journal of Heart Failure
[2] Deniau et. al. (2019) Circulating dipeptidyl peptidase-3 is a myocardial
depressant factor: DPP3 inhibition rapidly and sustainably improves
hemodynamics, European Journal of Heart Failure
[3] Siong Chan (2018) Proenkephalin in heart failure
[4] Hollinger et. al. (2018) Proenkephalin A 119-159 (Penkid) Is an Early
Biomarker of Septic Acute Kidney Injury: The Press Release Kidney in Sepsis
and Septic Shock (Kid-SSS) Study
[5] Beunders et. al. (2017) Proenkephalin (PENK) as a novel biomarker for
kidney function.
[6] Geven et. al. (2018) Geven 2018 Vascular effects of adrenomedullin and
the anti-adrenomedullin antibody Adrecizumab in sepsis
[7] Mebazaa et. al. (2018) Circulating adrenomedullin estimates survival and
reversibility of organ failure in sepsis: the prospective observational
multinational Adrenomedullin and Outcome in Sepsis and Septic Shock-1
(AdrenOSS-1) study
[8] ter Maaten et. al.(2019) Bio-adrenomedullin as a marker of congestion in
patients with new-onset and worsening heart failure ###
*About sphingotec *
SphingoTec GmbH ("sphingotec"; Hennigsdorf by Berlin, Germany) develops and
markets innovative in vitro diagnostic IVD tests for novel and proprietary
biomarkers for the diagnosis, prediction and monitoring of acute medical
conditions, such as acute heart failure, circulatory shock, and acute kidney
injury in order to support patient management and provide guidance for
treatment strategies. sphingotec's assay portfolio includes sphingotest(R)
bio-ADM(R) the assay for bioactive adrenomedullin, a unique biomarker for
real-time assessment of vascular integrity in conditions like sepsis or
congestive heart failure, sphingotest(R) penKid(R), the assay for
proenkephalin, a unique biomarker for real-time assessment of kidney
function and sphingotest(R) DPP3, an assay for Dipeptidyl Peptidase 3, a
unique biomarker for signaling pathway disruptions leading to acute organ
dysfunction. Along with the Nexus IB10 POC platform by its subsidiary Nexus
Dx Inc. (San Diego, CA, USA) acquired from Samsung in 2018, sphingotec
markets a standard marker portfolio for acute care. In addition, sphingotec
developed a portfolio of novel biomarkers, which predict the risks of
obesity, breast cancer and cardiovascular diseases.
*Contact:*
Ruxandra Lenz
PR and Market Communications Manager
_+ 49 3302 20565 34_
press@sphingotec.de [1]
End of Media Release
Issuer: SphingoTec GmbH
Key word(s): Health
2019-11-15 Dissemination of a Press Release, transmitted by DGAP - a service
of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
913877 2019-11-15
1: mailto:lenz@sphingotec.de
(END) Dow Jones Newswires
November 15, 2019 03:00 ET (08:00 GMT)
© 2019 Dow Jones News
